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Abstract
Activating mutations of FMS-like tyrosine kinase-3 (FLT3) are found in approximately 30% of patients with acute myeloid
leukemia (AML). FLT3 is therefore an attractive drug target. However, the molecular mechanisms by which FLT3 mutations
lead to cell transformation in AML remain unclear. To develop a better understanding of FLT3 signaling as well as its
downstream effectors, we performed detailed phosphoproteomic analysis of FLT3 signaling in human leukemia cells. We
identified over 1000 tyrosine phosphorylation sites from about 750 proteins in both AML (wild type and mutant FLT3) and B
cell acute lymphoblastic leukemia (normal and amplification of FLT3) cell lines. Furthermore, using stable isotope labeling
by amino acids in cell culture (SILAC), we were able to quantified over 400 phosphorylation sites (pTyr, pSer, and pThr) that
were responsive to FLT3 inhibition in FLT3 driven human leukemia cell lines. We also extended this phosphoproteomic
analysis on bone marrow from primary AML patient samples, and identify over 200 tyrosine and 800 serine/threonine
phosphorylation sites in vivo. This study showed that oncogenic FLT3 regulates proteins involving diverse cellular processes
and affects multiple signaling pathways in human leukemia that we previously appreciated, such as Fc epsilon RI-mediated
signaling, BCR, and CD40 signaling pathways. It provides a valuable resource for investigation of oncogenic FLT3 signaling
in human leukemia.
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Introduction
FMS-like tyrosine kinase-3 (FLT3) is a class III receptor tyrosine
kinase (RTK) that also includes C-KIT, C-FMS, and platelet-
derived growth factor receptor (PDGFR). Type III RTKs share a
common structure consisting of 5 extracellular immunoglobulin-
like domains, a single transmembrane domain, a cytoplasmic
juxtamembrane region, and a cytoplasmic kinase domain
interrupted by the kinase insert. FLT3 is primarily expressed in
early myeloid and lymphoid progenitors and plays an important
role in their proliferation and differentiation. In human acute
leukemia, FLT3 is expressed on the surface of the leukemic cells in
70–90% acute myeloid leukemia (AML) patients and most B-acute
lymphoblastic leukemia (B-ALL) [1,2,3].
Overexpression and activating mutations of receptor tyrosine
kinases (RTKs) are known to be involved in the pathogenesis of
many types of cancer. Mutations in FLT3 are commonly detected
in patients with AML. The most common of these mutations are
internal tandem duplications (ITDs), which occur in 25–30% of
these patients [4,5,6]. FLT3-ITDs are formed by duplication of a
fragment in the juxtamembrane domain that is always in frame
but varies in length. These mutations result in constitutive
activation of FLT3. In addition, FLT3 has been implicated in
the pathogenesis of infant and childhood ALL. Gene expression
analyses have shown that FLT3 is highly expressed in MLL-
rearranged acute lymphoblastic leukemias [7,8,9].
FLT3-ITDs activate many of the same signal transduction
pathways as the native receptor, such as RAS-MAPK pathway,
JAK-STAT pathway, PI3K, SRC, and phospholipase C-gamma
[10]. FLT3-ITDs are associated with poor prognosis for AML
patients [4,11,12] suggesting FLT3 or its downstream effectors as
potential therapeutic targets. Efforts to target FLT3 have led to the
development of several novel small molecule inhibitors. So far, the
results from the initial trials were somewhat ambiguous [13,14].
Thus, a better understanding of FLT3 signaling as well as its
downstream mediators could provide new insights into the
molecular mechanism and alternative drug targets for AML with
FLT3-ITD mutation. Recently, two large-scale phosphoproteo-
mics studies were performed from FLT3 mutant expressing BaF3
and 32D cell lines, and provide important insights into mutant
FLT3 signaling in murine systems [15,16]. Choudhary et al.
identified 61 tyrosine phosphorylation sites that were upregulated
by FLT3-ITD, and provided important information with regard to
spatial regulation of FLT3-ITD signaling [15].
To gain a global view of oncogenic FLT3 signaling in human
leukemia cells, we applied PhosphoScanH, an immunoaffinity-MS
profiling approach to leukemia cell lines containing activated
FLT3 mutations (FLT3-ITD and amplification) [17]. We
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19169identified many tyrosine phosphorylation sites unique to FLT3-
ITD human AML cell lines, including a novel site from FLT3. To
further investigate the FLT3 signaling pathway, we combined
PhosphoScanH, with stable isotopic amino acids in cell culture
(SILAC) to quantify changes in phosphorylation due to FLT3
inhibition in human leukemia cell lines. This experiment identified
many phosphorylation sites regulated by FLT3. Finally, we
identified novel protein phosphorylation sites from bone marrows
of primary AML patients, and shed light on FLT3 signaling
in vivo.
Results
Phosphotyrosine profiling of acute myeloid leukemia cell
lines
Whole cell lysates from 8 AML cell lines were digested with
trypsin, phosphopeptides were immunoprecipitated with phospho-
tyrosine antibody (pY-100), and analyzed by LC-MS/MS mass
spectrometry (IAP-MS) [17]. Data from duplicate experiments
were combined. Using this approach, we identified a total of 552
non-redundant phosphorylation sites in 513 proteins from 8 AML
cell lines (Table S1 and S2). These data have been deposited in
PhosphoSitePlus
TM (www.phosphosite.org). Based on protein
classification, cytoskeletal proteins, cell surface molecules, and
adaptor and scaffold proteins are the most highly phosphorylated
protein types (Figure 1A). Moreover, IGF1R and FLT3 are the
most abundantly phosphorylated receptor tyrosine kinases (RTKs)
in these cell lines (Figure 1B), consistent with their roles in the
pathogenesis of AML [18]. However, IGF1R is preferentially
phosphorylated in wild type FLT3 leukemia cell lines (Table S2).
On the other hand, LYN, HCK and BTK make up the majority of
cytoplasmic tyrosine kinases (CTKs) phosphorylation. In addition
to the two known FLT3 tyrosine phosphorylation sites (Y842 and
Y955) [19], we identified a novel FLT3 tyrosine phosphorylation
site (Y630) in MV(4;11) (Table S2). Y630 is located in the first part
of FLT3 split kinase domain. Its corresponding residue in the
mouse is FLT3 is Y631. The substitution of tyrosine to
phenylalanine at codon 631 did not impair the phosphorylation
of murine mutant form of FLT3
Asp838Val[20]. However, the role of
Y630 in the activation and signaling in the context of FLT3-ITD
needs to be determined.
Phosphotyrosine profiling of B-cell ALL cell lines
Since FLT3 is also involved in the pathogenesis of B cell acute
lymphoblastic leukemia (B-ALL), we investigated FLT3 tyrosine
signaling in three B-ALL cell lines, SEM, RS(4;11) and REH.
While SEM cells express high level of FLT3, RS(4;11) and REH
cells express relative low levels of wild type FLT3. In addition,
SEM, but not RS(4;11) and REH, is sensitive to FLT3 inhibitor[8]
(Figure S1A). Phosphotyrosine profiling identified a total of 533
non-redundant phosphorylation sites in 468 proteins from
duplicate runs of these cell lines (Table S1 and S2). Similar to
AML cell lines, cytoskeletal proteins, adaptor and scaffold, and
proteins involved in RNA processing are the top three protein
categories (Figure 1C). While FLT3 is the dominant RTK in these
B-ALL cell lines, LCK, LYN, and TEC represent the major CTKs
(Figure 1D), consistent with the role of these tyrosine kinases in
antigen receptor signaling in lymphocytes. Of note, two additional
FLT3 tyrosine phosphorylation sites (Y726 and Y969) were
detected in SEM cells (Table S2). Besides tyrosine phosphorylation
of FLT3 in SEM cells, we detected tyrosine phosphorylation of
proteins involving B cell receptor (BCR) signaling, such as CD19,
BCAP, LAB, BTK, LYN, GRB2, GAB1/2/3 [21,22,23,24,
25,26,27,28]. This observation raises the possibility that in
B-ALL FLT3 takes advantage of the BCR signaling complex to
promote B cell proliferation and survival.
Identification of MLN518-responsive tyrosine
phosphorylation sites
To find out a subset of phosphorylated proteins and their
respective sites that are regulated by FLT3, we employed stable
isotope labeling with amino acids in cell culture (SILAC) to
differentially label proteins derived from FLT3 inhibited versus
uninhibited leukemia cell lines. We used MLN518, a quinazoline-
based inhibitor of the type III receptor tyrosine kinases FLT3,
PDGFRA, CSF1R, and C-KIT[29]. MV(4;11), Molm 14, and
SEM are sensitive to MLN518 (Figure S1A). K562, which is
driven by BCR-ABL and insensitive to FLT3 inhibitors, was
included as a negative control. To address the off target effects of
MLN518, we checked the phosphorylation and expression of
CSF1R, C-KIT, and PDGFRA by Western blot analysis (Figure
S1B). Clearly, none of these kinases were phosphorylated and
expressed in the cell lines tested. Thus, FLT3 appears to be the
major target of MLN518 in MV(4;11), Molm 14, and SEM cells.
We set a 2-fold change in phosphopeptide intensity as a threshold
to define MLN518 sensitive site. From duplicate runs, we
identified 184 sites within 152 proteins and 39 sites within 33
proteins sensitive to MLN518 in MV(4;11) and Molm 14 cells,
respectively. Very few, if any, MLN518 sensitive sites were
observed in K562 cells (Table S3). Besides FLT3 tyrosine
phosphorylation, no other tyrosine kinases were greatly inhibited
by the treatment of MLN518 in these cell lines. Thus, most
MLN518 sensitive sites appear to be regulated by FLT3 directly or
downstream to FLT3. Of the proteins regulated by FLT3 many
fall within expected protein types, such as adaptor/scaffold,
proteins involved in cytoskeletal organization, enzymes, serine/
threonine kinases, and tyrosine kinases (Figure 2A). Others are
within protein types not previously associated with FLT3 signaling
such as RNA processing, cell surface proteins, and chaperones.
Notably, 27 of 28 proteins involving RNA processing identified in
MV(4;11) cells were regulated by FLT3 inhibitor, which may
reflect a cell type specific event. To further dissect signaling
pathways regulated by FLT3-ITD, we applied Gene Set
Enrichment Analysis (GSEA) [30] and identified Fc epsilon RI-
mediated signaling pathways, B cell receptor signaling, CD40,
IL2/3, and STAT3 pathways were enriched in FLT3-ITD
regulated phosphoproteins, some of which are known to be
involved in the pathogenesis of AML (Figure 2B).
Some of the known FLT3 regulated phosphorylation proteins
were significantly inhibited by MLN518, including FLT3 itself,
and its downstream effectors, SHC, STAT5A, and ERK. In
addition, we identified phosphorylation sites on adaptor proteins
previous linked to wild type FLT3 signaling, such as GAB2, SHP-
2, PLCG2, and SHIP1 [31,32,33,34,35]. Besides SHIP1, a more
ubiquitously expressed phosphatase (SHIP2) is also downregulated
by MLN518. Y986 on SHIP2 lies within a NPXY motif, which
may interact with SHC in response to FLT3 signaling. In addition,
quite a few phosphorylation sites on SRC family kinases were
sensitive to MLN518, such as HCK, LYN, LCK, FYN, and FGR.
This observation is consistent with the proposed role of SRC
family kinases, especially LYN, in FLT3 signaling [36]. Some of
these SILAC-MS results were further confirmed by Western blot
analysis (Figure 3).
In addition to FIT3-ITD AML cell lines, we identified a total of
160 MLN518 sensitive sites from 120 proteins in SEM cells,
significantly extended our knowledge of FLT3 signaling in ALL.
Adaptor/scaffold, cytoskeletal proteins, cell surface molecules, and
adhesion/extracellular matrix proteins make up the majority of
FLT3 Signaling in Leukemia
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receptor signaling, integrin, growth hormone, and Fc epsilon RI-
mediated signaling pathways were highlighted (Figure 2D). Besides
Y842, two additional sites on FLT3 (Y630 and Y726) were
inhibited by MLN518. Moreover, tyrosine phosphorylation of
several components of B cell receptor (BCR) signaling pathways
was also inhibited, including CD19, LAB, BCAP, LYN, BTK,
GRB2, and GAB1/2/3. We confirmed a subset of phosphoryla-
tion sites by Western blot using phosphospecific antibodies,
including BCAP, GAB1, and GAB2 (Figure 4). These results
suggest that instead of activating novel signaling pathways, FLT3
utilizes components of BCR signaling pathway to promote
proliferation and survival of lymphoid cells in B cells acute
lymphoblastic leukemia. Some of the tyrosine phosphorylation
sites regulated by MLN518 were further confirmed by Western
blot with another FLT3 inhibitor, Sorafenib (Figure S2).
Figure 1. Phosphotyrosine profiling of AML and B-ALL cell lines. (A) Distribution of phosphoprotein types in AML cell lines. Each observed
phosphoprotein was assigned a protein category from PhosphoSite ontology. The numbers of unique proteins in each category, as a fraction of the
total, are presented. (B) Distribution of receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (CTKs) in AML cell lines. The total number of
spectral counts of each RTK/CTK is normalized against total number of phosphopeptides of GSK3A (100) in each sample, then the sum of the
normalized number of each RTK/CTK as fractions of the total are shown. (C) Distribution of phosphoprotein types in B-ALL cell lines. Each observed
phosphoprotein was assigned a protein category from PhosphoSite ontology. The numbers of unique proteins in each category, as a fraction of the
total, are presented. (D) Distribution of receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (CTKs) in B-ALL cell lines. The total number
of spectral counts of each RTK/CTK is normalized against total number of phosphopeptides of GSK3A (100) in each sample, then the sum of the
normalized number of each RTK/CTK as fractions of the total RTK spectra were represented.
doi:10.1371/journal.pone.0019169.g001
FLT3 Signaling in Leukemia
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threonine phosphorylation sites
Because FLT3 receptor signaling engages the MAPK pathway
and also regulated the cell cycle [37], we applied the same
immuno-affinity profiling strategy, but using instead of a phospho-
tyrosine antibody, two phospho-specific antibodies that recognize
the PXSP and PXTP motifs, which are common substrate
recognition motifs of MAPKs and CDKs. In brief, SILAC
supernatants (after pY-100 immunoprecipitation) from MV(4;11),
SEM, and K562 cells were sequentially immunoprecipitated with
PXSP and PXTP motif antibodies, and analyzed by LC-MS/MS
mass spectrometry. In MV(4;11) cells, we identified 150 sites from
88 proteins that are sensitive to MLN518 (Figure 2E and Table
S3), 21% of them are from transcription factors. Consistent with
this finding, gene ontology (GO) analysis revealed that biological
processes, such as chromatin modification and regulation of
transcription, were significantly enriched (Figure 2F). Among
FLT3 regulated serine sites, phosphorylation of p70S6K
Ser424 was
further confirmed by Western blot with phospho-specific antibody
(Figure S1C), locating this growth promoting kinase downstream
to FLT3 in leukemic cells. In addition, FLT3 regulates
phosphorylation of NFkB-p105
Ser907, a precursor of the NFkB-
p50 subunit. Dephosphorylation of NFkB-p105
Ser907 accelerates
the processing of p105 to p50 [38,39]. ERF
Thr526 is one of the sites
most inhibited by MLN518 in MV(4;11). ERF, an ets domain
transcriptional repressor, serves as a link between RAS/MAPK
pathway and cell cycle progression [40]. Phosphorylation of
ERF
Thr526 by ERK renders it unable to repress c-myc and cdc2
expression [41]. Thus, ERF maybe a target for inactivation by
FLT3, possibly linking FLT3 with c-myc de-regulation in AML.
Figure 2. Classes of tyrosine and serine/threonine phosphorylated proteins that are responsive to FLT3 inhibitor. (A) and (B) Classes
of proteins in which phosphotyrosine sites were identified in response to FLT3 inhibitor in MV(4;11) and Molm 14 AML cell line,. Only the top 8 classes
were shown, the rest were classified as other. GSEA analysis revealed top ranked pathways that are enriched in drug sensitive tyrosine
phosphorylated proteins using curated gene sets from molecular signature database. (C) and (D) Classes of proteins in which phosphotyrosine sites
were identified in response to FLT3 inhibitor in SEM cell line. GSEA analysis revealed top ranked pathways that are enriched in drug sensitive tyrosine
phosphorylated proteins using curated gene sets from molecular signature database. (E) and (F) Classes of proteins in which PXSP/PXTP sites were
identified in response to FLT3 inhibitor in MV(4;11) cell line. BiNGO Gene Ontology (GO) analysis reveals cellular processes or pathways enriched in
drug sensitive serine/threonine phosphorylated proteins.
doi:10.1371/journal.pone.0019169.g002
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ferase (MLL2) and histone demethylase (FBXL11), suggesting that
FLT3 may play a role in epigenetic regulation. It is interesting to
note that FLT3 activation leads to phosphorylation of AML1 on
both serine (249 and 276) and threonine sites (273), possibly
through an ERK dependent mechanism [42]. While we identified
many MLN518 sensitive tyrosine sites in SEM cells, we observed
very few PXSP/PXTP sites in SEM cells, including ERF, CapZIP,
and AML1 (Table S3).
Global phosphorylation profiling of bone marrow cells
from AML patient samples
To understand the role of FLT3 activation in primary patients,
we profiled bone marrow cells from AML samples with known
FLT3 mutational status. We identified 209 tyrosine phosphoryla-
tion sites from over 200 proteins in 6 AML patients, three of which
contains FLT3-ITD mutation (Table S1 and S2). We detected
FLT3 tyrosine phosphorylation at its activation loop (Y842) in all
three FLT3-ITD patients (Table S2). Of note, tyrosine phosphor-
ylation of STAT5, a major downstream target of FLT3, was only
present in FLT3-ITD patients. Phosphorylation of FLT3 was also
detected in one wild type FLT3 case, consistent with the
observation that FLT3 is expressed in a high percentage of
AML patients. SRC family kinases, LYN and LCK, were
abundantly phosphorylated on their activation sites in these
AML samples, consistent with the importance of activation of
SRC family kinases in AML survival [43]. 48 MLN518 sensitive
tyrosine phosphorylated proteins from adaptor/scaffold, tyrosine
kinases, serine/threonine kinases, and other protein types, found
in FLT3-ITD AML cell lines are also present in these FLT3-ITD
patients (Figure 5A and 5B, Table S4), suggesting that these
proteins might play important roles of FLT3-ITD signaling in
vivo.
Besides phosphotyrosine profiling, we performed IAP-MS
analysis with PXSP and PXTP motif antibodies on these AML
patients, and identified 859 serine/threonine sites from 486
proteins (Table S1 and S2). Many MLN518 sensitive pSer/Thr
sites identified in MV(4;11) cell line are also present in FLT3-
ITD AML patients, such as p70S6K
Ser424, NFkB-p105
Ser907,
AML
Ser249,276,Thr273, and ERF
Thr526. Overall, we identified 70
drug sensitive serine/threonine phosphorylated proteins (tran-
scription factors, cytoskeletal proteins, adaptors, and others) in 3
FLT3-ITD patients (Figure 5C and 5D, Table S4). Overall, we
identified 117 FLT3 regulated tyrosine and serine/threonine
Figure 3. Western blot analysis confirms FLT3 inhibitor responsive pTyr-sites in AML cell lines. (A), (B), (C), and (D) Immunoblotting of
MV(4,11) and Molm 14 cells treated with 2 uM FLT3 inhibitor (MLN518) for 2 hours with different phospho-specific antibodies. HEL and K562 cells
were included as controls.
doi:10.1371/journal.pone.0019169.g003
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are from different cellular compartments and involved in diverse
cellular processes, only a few of them have direction interactions
with FLT3 (Figure 5E). Thus, this study expanded our
understanding of FLT3 signaling in vivo.
Discussion
Deregulated tyrosine kinases have been frequently implicated in
the pathogenesis of cancer, including AML [44]. However,
tyrosine phosphorylation represents less than 2% of total protein
phosphorylation [45,46], making the study of phosphorylated
tyrosine residue challenging. For the past decade, our knowledge
of FLT3 signaling pathways has been painstakingly accumulated,
mainly through the study of individual molecules in certain
pathways. In our study, using PhosphoScanH, a phosphotyrosine
profiling proteomics approach we profiled 11 leukemia cell lines (8
AML and 3 B-cell ALL), and six primary AML patients. We
identified over 1000 tyrosine phosphorylated sites from about 800
proteins. Our study significantly expands the inventory of
phosphorylated proteins associated with FLT3 signaling in human
AML and B-ALL. Our data thus provide a unique insight into in
vivo FLT3 signaling components and their relevant regulatory
sites. This global, unbiased view of the in vivo phosphoproteome
revealed a large number of cellular proteins phosphorylated, and
identified an important subset of proteins and their phosphoryla-
tion sites regulated in response to FLT3 inhibitor.
Recent Studies done by Choudhary et al. and Zhang et al., which
represent the first two large-scale Phospho-profiling of mutant
FLT3 signaling, provide broad view of oncogenic FLT3 signaling to
date. However, these studies were performed with overexpression of
mutant FLT3 in murine systems. In contrast to the study done by
Choudhary et al., which was performed with PKC412 for 12 hours,
our study was done with MLN518 for 2 hours, which reflects early
changes in protein phosphorylation. We observed FLT3 regulates
tyrosine phosphorylation in protein kinases, adaptor/scaffold
proteins, and phosphatase. In addition, some FLT3 regulated sites
are tied to many previously unknown cellular systems, as
demonstrated here by identification of regulated sites on cell surface
proteins, cytoskeletal proteins, RNA processing proteins and other
important protein classes. The diversity of protein classes found to
be regulated by FLT3 inhibitor suggests that FLT3 affects a broad
spectrum of signaling pathways and cell functions not limited to
proliferation and survival. For example, Y399 of DNMT1 is a drug
sensitive site, raising the possibility that that FLT3-ITD regulates
the activity of DNMT1, and affects global DNA methylation
patterns in FLT3-ITD leukemic cells. Not only does FLT3 activate
tyrosine signaling pathways, but it also regulates epigenetic events
through phosphorylation of transcription factors on serine/
threonine residues. Future studies should be aimed at connecting
these data directly to downstream gene-expression changes as
measured by microarray technology.
Some of the FLT3 regulated proteins contained more than one
regulated site, such as Y67, 88, and 139 of cofilin1 in MV(4;11)
Figure 4. Western blot analysis confirms FLT3 inhibitor responsive pTyr-sites in B-ALL cell lines. (A), (B), and (C) Immunoblotting of SEM
cells treated with 2 uM FLT3 inhibitor for 2 hours with different phospho-specific antibodies. RS(4,11) and REH cells were included as controls.
doi:10.1371/journal.pone.0019169.g004
FLT3 Signaling in Leukemia
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also showed that phosphorylation of different sites within the same
protein can also be differentially regulated. For example, Y383
and Y598, but not Y208 on GIT1 (G protein-coupled receptor
kinase interactor 1) are responsive to MLN518 In MV(4;11). A
similar observation was made for tyrosine sites on ENO1 and
HCK. This highlights the importance of measuring the degree of
site-specific phosphorylation rather than phosphorylation the
protein as a whole in order to obtain an accurate picture of a
protein’s function.
In SEM cells, we observed multiple FLT3 regulated sites on key
elements of B-cell receptor signaling pathways such as BCAP,
CD19, LAB, DOK1, GAB1, and GAB2. In addition, we
confirmed phosphorylation of BCAP is regulated by FLT3. BCAP
binds PI3K and plays an essential role in B cell development
[26,28]. However, immunoprecipitation with FLT3 antibody did
not pull down CD19, BCAP and LAB (data not shown). Thus,
FLT3 might indirectly regulate tyrosine phosphorylation of these
proteins. Since B cell receptor signaling is involved in B cell
development, activation and differentiation [25], oncogenic FLT3
might provides proliferative and survival signal for B cells by
regulating components of B cell receptor signaling. It is plausible
that oncogenic FLT3 may cooperate with other oncogenic events
such as MLL fusions to promote leukemogenesis of B-ALL [47].
In this study, we identified five FLT3 tyrosine phosphorylation
sites in primary leukemia cell lines, adding new information on
how phosphorylation may affect the activity of wild-type FLT3
and FLT3-ITD. FLT3 has been implicated in the pathogenesis of
both AML and B-ALL. We observed that in both AML and B-
ALL cell lines, FLT3 activates many of the similar signaling
pathways, such as JAK-STAT pathway, RAS-MAPK pathway,
and phospholipase C-gamma (Figure 3 and 4). Yet, a key
difference is the apparent recruitment of the BCR complex by
FLT3 in B-ALL. Our data is therefore consistent with the
observation that FLT3 inhibitors have therapeutic effects in B cell
acute lymphoblastic leukemia with high level of FLT3 expression
[8]. This suggests that FLT3 pathogenesis in B-ALL could depend
on elements of that pathway which could be additionally targeted
by tailored therapies.
When we compared phosphotyrosine profile between two
FLT3-ITD cell lines (MV(4;11) and Molm 14) and three FLT3-
ITD AML patients, we noticed that 77% (130 out of 168) of
phosphoproteins identified in AML patients were also present in
these two cell lines, suggesting that FLT3-ITD cell lines are good
models to understand FLT3-ITD signaling for primary patients
(Figure S3). On the other hand, there are a large number of
phosphoproteins identified in FLT3-ITD cell lines not present in
primary patients. It could be due to the lengthy period required to
collect bone marrow and lyse red blood cells, during which a
significant amount of tyrosine phosphorylation events were lost.
Nonetheless, tyrosine phosphorylated proteins, like FLT3,
ESYT1/2 (FAM62A/B), HGS, HSP90AA, INPPL1(SHIP-2),
LYN, SF3B4, SHC1, STAT5A, and VASP, are not only enriched
in Molm14 and MV(4;11) cell lines with statistical significance
(FDR,0.05) and regulated by FLT3 inhibitor, but also present in
FLT3-ITD AML patients. While some of these proteins are known
components of FLT3 signaling pathways, the function of other
proteins remain to be determined.
Several small molecule FLT3 inhibitors are in phase I/II
clinical trials. However, the fundamental relationship between
FLT3 inhibition, its consequences on downstream signaling, and
the onset of cytotoxicity remains poorly understood [13]. A recent
study showed that cytotoxic responses to CEP-701 and PKC412
were highly heterogeneous and were only weakly associated with
FLT3 expression level and mutation status [48]. Clearly, if FLT3
small molecule inhibitors were to have an impact on AML
treatment, a better understanding of how FLT3 signaling
contributes to the disease, and how FLT3 drugs work at the
cellular level, would be necessary. This study not only provides a
comprehensive view of FLT3 regulated signaling pathways in
human AML cell lines, but also gives us an initial glance onto the
activation of these pathways in primary AML patient samples. We
showed that oncogenic FLT3 affects multiple signaling pathways
in human AML patients and regulates proteins from different
cellular compartment and diverse cellular processes. Targeting
pathways of Fc epsilon RI-mediated signaling, MAPK, BCR, and
CD40 signaling may offer new hope to treat FLT3-ITD AML.
This study opens the door to a deeper understanding of FLT3
signaling networks, to identify novel and better biomarkers to trace
clinical response to FLT3 inhibitors. In addition, this study
provides a valuable resource for the scientific community to
further investigate oncogenic FLT3 signaling in primary AML
patients.
Materials and Methods
Cell culture and AML patient samples
8 human AML cell lines (MV(4;11), Molm 14, Marimo, Me-F2,
KY821, OCI/AML3, Nomo-1, and ML-1) and 3 human B-ALL
cell lines (SEM, RS(4;11), and REH) were included in mass
spectrometry analysis. Both MV(4;11) and Molm 14 contain
FLT3-ITD mutation. SEM contains amplified copy number of
FLT3. Detailed history about these cell lines were provided in
table S1. K562 cells were obtained from American Type Culture
Collection (ATCC). OCI/AML3, Nomo-1, GDM-1, HEL, M-
07e, SEM, RS(4;11), and REH cells were obtained from the
German National Resource Centre for Biological Material
(DSMZ). M-07e was grown in 80%IMDM with 20%FBS, plus
10 ng/ml GM-CSF. All other cell lines were grown in RPMI-1640
with 10% FBS. Cells were treated for 2 hours (immunoblotting
and SILAC) with 2 uM MLN518 (Tandutinib, a FLT3 inhibitor
from Millennium Pharmaceuticals, Inc., The Takeda oncology
company) before lysis. For dose response curves, cells were
incubated for 48 hours in the presence of different concentration
of MLN518, and the number of viable cells was determined with
the CellTiter 96 AQueous One solution cell proliferation assay
(Promega). Collection and use of de novo AML patient bone
marrow samples were approved by the human subjects Institu-
tional Review Boards of Oregon Health & Science University and
Portland VA Medical Center with written consent from patients.
Patient information was not revealed in this study, and the data
were analyzed anonymously.
Figure 5. Presence of FLT3 regulated phosphoproteins in FLT3-ITD primary AML patients. (A) and (B) Venn diagram showed that MLN518
sensitive tyrosine phosphorylated proteins (.=2 fold) identified in FIT3-ITD cell lines were also present in FLT3-ITD primary AML patients. Pie chart
showed the protein types of these overlapped proteins. (C) and (D) Venn diagram showed that MLN518 sensitive serine/threonine phosphorylated
proteins (.=2 fold) identified in FIT3-ITD cell lines were also present in FLT3-ITD primary AML primary patients. Pie chart showed the protein types of
these overlapped proteins. (E) Regulatory networks of FLT3 signaling that have in vivo relevance. Phosphoproteins in the network were derived from
proteins in the overlapped region in figure 5A and 5C.
doi:10.1371/journal.pone.0019169.g005
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LC-MS/MS Mass Spectrometry
Phosphopeptides were prepared using PhosphoScanH Kit (Cell
Signaling Technology). Briefly, about 2610
8 cells (or 1610
8 bone
marrow cells) were lysed in urea buffer, trypsin digested lysate
were purified by Sep-pak C18 column. Then, lyophilized peptides
were redissolved and immunoaffinity purified with pY-100
antibody, which interacts with a broad range of tyrosine-
phosphorylated peptides. pTyr-containing peptides were concen-
trated on reverse-phase micro tips. Supernatants after pY-100
immunoprecipitation were further immunoaffinity purified with
PXSP and PXTP (Phospho-MAPK/CDK substrate) motif
antibodies, which detect phospho-serine in a PXS*P or phospho-
threonine in a PXT*P motif. Tandem mass spectra (ms/ms) were
collected in a data-dependent fashion with an LTQ ion trap mass
spectrometer or and LTQ-Orbitrap mass spectrometer (Thermo-
Finnigan) in which the top 10 ions were selected for ms/ms.
Sequest (Thermo Fisher Scientific) searches were done against the
NCBI human database released on July 02, 2009, (containing
37,391 proteins), allowing for phosphorylation (STY+80) and
oxidized methionine (M+16) as differential modifications using a
precursor tolerance of 1.2 Da for LTQ data or 50 ppm LTQ
Orbitrap data. LTQ data was searched fully tryptic, while
Orbitrap data was searched with partial tryptic specificity. The
PeptideProphet probability threshold was chosen to give a false
positive rate of 1% for the peptide identifications (Table S1) [49].
Phosphorylation sites were localized using the Ascore[50]. Data
from duplicate experiments were combined.
SILAC analysis of MLN518-treated cells
MV(4;11), Molm 14, SEM, and K562 cells were grown in
RPMI-1640 (lacking arginine and lysine) supplemented with 10%
dialyzed fetal bovine serum, and L-lysine/HCl and L-arginine/
HCl (Sigma, St Louis, MO) for light cultures or L-arginine/HCl
(U-13C6, 98%) and L-lysine:2 HCl (U-13C6, 98%; U-15N2, 98%)
(Cambridge Isotope Laboratories, Andover, MA) for heavy
cultures, as previously described [51,52,53]. After lysis, 1610
8
cells from either heavy or light cultures were combined and carried
through the phosphopeptide immunoprecipitation protocol.
Methods for LTQ-FT MS, Sequest searches and Vista (pTyr,
pSer, and pThr SILAC samples) were described previously
[54,55].
Statistical and computational analysis
We used the following statistical and computational tools from
Gene Set Enrichment Analysis (GSEA, Broad Institute of MIT
and Harvard) for Molecular Signature Database analysis;
BIOBASE Knowledge Library for Gene Ontology analysis.
STRING 8.2 for potential protein protein interaction analysis
[56].
Western blotting
Cells were lysed in 16 cell lysis buffer (Cell Signaling
Technology) supplemented with Protease Arrest
TM (G Biosciences)
and separated by electrophoresis. All antibodies and reagents for
immunoblotting were from Cell Signaling Technology, Inc.
Supporting Information
Figure S1 FLT3-ITD cell lines are sensitive to its
inhibitor. (A) Sensitivity of AML and B-ALL cell lines to
FLT3 inhibitor (MLN518). % control means percent of viable cells
after drug treatment as compared to untreated control.
(B) Phosphorylation and expression of CSF1R, C-KIT, and
PDGFRA in leukemia cell lines. GDM-1, M-07e, and H1703 cell
lines are positive controls for the expression of CSF1R, C-KIT,
and PDGFRA, respectively. (C) Phosphorylation of p70S6 kinase
is inhibited by FLT3 inhibitor.
(TIF)
Figure S2 Western blot analysis confirms MLN518
responsive pTyr-sites in AML and B-ALL cell lines by
Sorafenib treatment. (A), (B), and (C) Immunoblotting of
MV(4,11), Molm 14, and SEM cells treated with 100 nM FLT3
inhibitor (sorafenib) for 2 hours with different phospho-specific
antibodies. K562 cells were included as controls.
(TIF)
Figure S3 Venn diagram showed the overlap of tyrosine
phosphorylated proteins identified between two FLT3-ITD
AML cell lines and three FLT3-ITD primary AML patients.
(TIF)
Table S1 Phosphopeptides identified by LC-MS/MS in AML
and B-ALL cell lines, as well as primary AML patients. P1–P3 are
FLT3 wild type AML patients, P4–P6 are FLT3-ITD AML
patients. ‘Y*’, ‘S*’/, and ‘T*’ in peptide indicates phosphorylated
tyrosine, serine, or threonine residue, respectively. Spectra links
were provided, as well as other important mass spectrometry
parameters (XCorr, Ascore, etc.). False discovery rate (fdr) for each
dataset was also listed.
(XLS)
Table S2 Non-redundant phosphopeptides identified by LC-
MS/MS in this study presented in a format that is based on
individual cell line or AML patient. ‘y’, ‘s’, and ‘t’ in peptide
indicates phosphorylated tyrosine, serine, or threonine residue,
respectively. Data from duplicate experiments were combined.
Tyrosine kinases profile in AML cell lines and patients were
summarized as well. ‘1’ indicates known phosphorylation site.
(XLS)
Table S3 Phosphotyrosine SILAC data of MV(4,11), Molm 14,
SEM, and K562 cell lines, and phosphoserine (PXSP) and
phosphothreonine (PXTP) SILAC data of MV(4,11), SEM, and
K562 cell lines, treated with FLT3 inhibitor (MLN518). ‘Y*’ ‘s’,
and ‘t’ in peptide indicates phosphorylated tyrosine, serine, or
threonine residue, respectively. ‘1’ indicates known phosphoryla-
tion. Results from duplicate run were combined.
(XLS)
Table S4 List of proteins and their protein types identified in
SILAC study of FLT3-ITD cell lines (.=2 fold) that were also
present in three FIT3-ITD primary patients. Both tyrosine
phosphorylated and serine/threonine phosphorylated proteins
were listed.
(XLS)
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